|
|
| | Taurochenodeoxycholic acid Basic information |
| Product Name: | Taurochenodeoxycholic acid | | Synonyms: | 2-(4-(3,7-dihydroxy-10,13-diMethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanaMido)ethanesulfonic acid;Taurocholic chenodeoxycholic acid;2-((R)-4-((3R,5S,7R,8R,9S,10S,13R,14S,17R)-3,7-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic acid;2-[4-(3,7-dihydroxy-10,13-;Taurochenodeoxycholic acid;C05465;Chenodeoxycholoyltaurine;12-Deoxycholyltaurine | | CAS: | 516-35-8 | | MF: | C26H45NO6S | | MW: | 499.7 | | EINECS: | | | Product Categories: | Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Steroids;516-35-8 | | Mol File: | 516-35-8.mol |  |
| | Taurochenodeoxycholic acid Chemical Properties |
| Melting point | 186-200°C | | density | 1.216±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | Chloroform, Methanol | | form | Solid | | pka | 1.42±0.50(Predicted) | | color | White to Pale Beige |
| | Taurochenodeoxycholic acid Usage And Synthesis |
| Uses | Labelled analogue of Taurochenodeoxycholic Acid, a bile acid conjugate and metabolite Taurolithocholic Acid (T009100) with antiinflammatory activity. Taurochenodeoxycholic Acid has been shown to inhibit hepatocyte apoptosis through suppression of Bid translocation to mitochondria. | | Uses | Taurochenodeoxycholic Acid is a bile acid conjugate and metabolite Taurolithocholic Acid (T009100) with antiinflammatory activity. Taurochenodeoxycholic Acid has been shown to inhibit hepatocyte apoptosis through suppression of Bid translocation to mitochondria. | | Definition | ChEBI: A bile acid taurine conjugate of chenodeoxycholic acid. | | in vivo | Taurochenodeoxycholic acid (12-Deoxycholyltaurine; 0.05, 0.1g/kg) decreases the pulmonary coefficient in the model mice and reduces the pathological damages on their lungs; it can decrease the expression levels of TNF-α and TIMP-2 in pulmonary tissues in the pulmonary fibrosis mice and has no significant effects on MMP2[2].
?
Taurochenodeoxycholic acid significantly normalizes the clinical inflammatory parameters, prevented indomethacin-induced increases in the biliary contents of secondary bile acids and hydrophobicity index, and tended to attenuate the intestinal inflammation[3].
?
Taurochenodeoxycholic acid significantly suppresses paw swelling and polyarthritis index, increases the loss body weight and index of thymus and spleen, and amends radiologic changes in AA rats. The overproduction and mRNA expression of TNF-α, IL-1β and IL-6 are remarkably suppressed in serum and synovium tissue of all TCDCA-treated rats[4].
| | IC 50 | Microbial Metabolite; Human Endogenous Metabolite |
| | Taurochenodeoxycholic acid Preparation Products And Raw materials |
|